Indofarma Tbk PT
IDX:INAF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Indofarma Tbk PT
PP&E Gross
Indofarma Tbk PT
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indofarma Tbk PT
IDX:INAF
|
PP&E Gross
Rp328.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
PP&E Gross
Rp3.6T
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
PP&E Gross
Rp8.7T
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
PP&E Gross
Rp499.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
PP&E Gross
Rp2.4T
|
CAGR 3-Years
41%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
PP&E Gross
Rp8.7T
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
29%
|
|
Indofarma Tbk PT
Glance View
PT Indofarma Tbk is engaged in the pharmaceutical and healthcare businesses. The company is headquartered in Bekasi, Jawa Barat and currently employs 1,095 full-time employees. The company went IPO on 2001-04-17. The firm's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The firm carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.
See Also
What is Indofarma Tbk PT's PP&E Gross?
PP&E Gross
328.2B
IDR
Based on the financial report for Sep 30, 2025, Indofarma Tbk PT's PP&E Gross amounts to 328.2B IDR.
What is Indofarma Tbk PT's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
-7%
Over the last year, the PP&E Gross growth was -17%. The average annual PP&E Gross growth rates for Indofarma Tbk PT have been -11% over the past three years , -7% over the past five years .
